<DOC>
	<DOCNO>NCT00471978</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help study cancer future . PURPOSE : This clinical trial analyze DNA blood tissue sample patient lung cancer .</brief_summary>
	<brief_title>DNA Analysis Blood Tissue From Patients With Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Assess role genetic polymorphism lung-cancer risk patient lung cancer . - Assess role germline polymorphisms DNA repair gene , p53 pathway gene , matrix metalloproteinase gene ( tumor invasion factor ) lung-cancer risk , adjust potential confounders . - Assess role gender age genetic susceptibility lung cancer . - Assess role genetic polymorphism modify diet-lung cancer risk association ( gene-diet exploratory gene-gender-diet gene-gene-diet interaction ) . - Assess role polymorphism risk develop specific histologic subtypes lung cancer case-only analysis . - Determine whether continued exposure mainstream and/or second-hand tobacco smoking associate poorer clinical prognosis patient treat lung cancer . OUTLINE : This case-control study . Blood sample collect patient control . Samples analyze polymerase chain reaction gene polymorphism . Genes study include GSTP1 , GSTM1 , GSTT1 , ERCC2 , XRCC1 , EPHX , NAT-2 , p53 gene , CYP1A1 , NQO1 , MnSOD , GPX1 . Tissue sample collect patient undergo surgery blood sample archive future study . Patients control complete questionnaire diet , medical history , occupational/environmental history . PROJECTED ACCRUAL : A total 3,400 patient 3,400 control accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patient : Newly diagnose lung cancer Patient Massachusetts General Hospital ( MGH ) Boston Medical Center Cancer Center Control : Nonbloodrelated friend spouse patient No specific match characteristic Friend spouse hospital patient PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : Not specify EXCLUSIONS : Healthy control primary cancer ( melanoma , colon , etc . ) exclude Vulnerable population exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
	<keyword>pulmonary carcinoid tumor</keyword>
</DOC>